Table of Contents

company-logo

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialisation of cannabinoid-based medicines for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company also provides OTC products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as ITURA, an advanced relief cream formula that targets multi-symptoms, such as numbness and tingling, muscle cramps, insensitivities, and pain associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has strategic partnerships with Curtin University; the Telethon Kids Institute; the University of Western Australia; St. Vincent's Hospital; and the Children's Hospital of Philadelphia. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.

Zelira Therapeutics Dividend Announcement

• Zelira Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Zelira Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Zelira Therapeutics Dividend History

Zelira Therapeutics Dividend Yield

Zelira Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Zelira Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Zelira Therapeutics Financial Ratios

P/E ratio-0.22
PEG ratio-0.00
P/B ratio-1.76
ROE1066.85%
Payout ratio0.00%
Current ratio0.60
Quick ratio0.42
Cash Ratio0.08

Zelira Therapeutics Dividend FAQ

Does Zelira Therapeutics stock pay dividends?
Zelira Therapeutics does not currently pay dividends to its shareholders.
Has Zelira Therapeutics ever paid a dividend?
No, Zelira Therapeutics has no a history of paying dividends to its shareholders. Zelira Therapeutics is not known for its dividend payments.
Why doesn't Zelira Therapeutics pay dividends?
There are several potential reasons why Zelira Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Zelira Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Zelira Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Zelira Therapeutics a dividend aristocrat?
Zelira Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Zelira Therapeutics a dividend king?
Zelira Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Zelira Therapeutics a dividend stock?
No, Zelira Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Zelira Therapeutics stocks?
To buy Zelira Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Zelira Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.